(lp0
S"Dendreon Files for Bankruptcy as Cancer Drug Disappoints Bloomberg - Nov 10, 2014 Dendreon Corp., the maker of prostate-cancer drug Provenge, filed for bankruptcy protection, potentially wiping out shareholders in a company that pioneered the use of patients' immune systems to fight tumors.Dendreon, Maker of Prostate Cancer Drug Provenge, Files for Bankruptcy - New York TimesDendreon files for Chapter 11 bankruptcy - Reuters"
p1
aS"Dendreon Gets Nod For Ch. 11 Liquidation Plan Law360  - Jun 2, 2015 Law360, Wilmington  -- A Delaware bankruptcy judge on Tuesday blessed Dendreon Corp.'s proposed Chapter 11 plan, allowing the cancer treatment developer to dole out remaining proceeds from its $495 million sale to&nbsp;..."
p2
aS'Stock to Watch Dendreon Corporation  MicroCap Daily - Feb 10, 2015 Dendreon Corporation  continues to be highly volatile in recent days after the Company announced a strong Commercial Start to 2015.'
p3
aS'Todays Stock in Focus: Dendreon Corporation  MicroCap Daily - May 20, 2015 Dendreon Corporation  is moving lower on accelerating volume after eclipsing $0.05 where it had some support.'
p4
aS"Investors Are in Love With Dendreon Corporation Motley Fool - Mar 4, 2014 While spending 51% of the sales price to make the drug is better than the 69% it spent in the third quarter, but it's still 51%!Dendreon Announces Plans to Make PROVENGE - Business Wire Sipuleucel-T Soon Available to Patients in Europe and Beyond - OncLive"
p5
aS"What Does Dendreon Corporation's Fourth Quarter Mean For Investors? Motley Fool - Feb 2, 2014 Dendreon's  Provenge continues to be hotly debated among investors. The drug, which harnesses the immune system as a cancer-fighting weapon, is used to treat patients suffering from metastatic castration resistant prostate cancer,&nbsp;..."
p6
aS"Dendreon Gets OK For Sweetened $495M Sale To Valeant Law360  - Feb 20, 2015 Law360, Wilmington  -- A Delaware bankruptcy judge gave the nod Friday to Dendreon Corp.'s sale to a unit of Valeant Pharmaceuticals International Inc., approving a sweetened deal that increased the purchase price from&nbsp;...Valeant Pharmaceuticals gets OK to buy bankrupt Dendreon for $495 million - Puget Sound Business Journal  Dendreon's Enhanced $445 Million Sale to Valeant Approved - Bloomberg"
p7
aS'Is It Time To Give Up On Dendreon? Seeking Alpha - May 7, 2013 What happened to Seattle, Washington-based Dendreon Corporation ? There was once so much optimism and excitement about this biotechnology company pioneering active cellular immunotherapy  technology to develop drugs that&nbsp;...'
p8
aS"Dendreon's Provenge Revenue Trends Seeking Alpha - Jan 9, 2013 Provenge seems to be in a run rate of $320 million per year, which would be a pretty successful drug if its cost of production were more normal and if it was one of many therapies of a corporation. But at $320 million per year it makes Dendreon a money ..."
p9
aS'Dendreon Corporation  Gets Approval Of Sale From The Bankruptcy ... Traders350 - Feb 23, 2015 Dendreon Corporation  received approval of the Bankruptcy Court for an order authorizing sale transaction to Valeant Pharmaceuticals International, Inc.  pursuant to the acquisition agreement.Valeant buys bankrupt drug maker Dendreon for $495 million - GeekWire'
p10
a.